New Study for Treatment of Relapsed B-cell Lymphoma in Dogs

TANOVEA®-CA1 (rabacfosadine for injection) is a novel double prodrug that targets cancerous lymphoma cells and is the first FDA conditionally approved drug for the treatment of lymphoma in dogs. Previous studies have suggested that administration of rabacfosadine every 3 weeks can achieve … Keep Reading

An Update on Canine Lymphoma Treatment

Tuesday April 21, 2017 FORT COLLINS (vetStreet, By Dr. Ann Hohenhaus DVM, DACVIM (SAIM, Oncology)) — If you have the unfortunate opportunity to spend time in a veterinary oncologist’s waiting room and decide to strike up a conversation with other … Keep Reading

VetDC announces commercial launch of canine lymphoma drug

Tuesday April 4, 2017 FORT COLLINS (InnovatioNews, Terry Opgenorth) — VetDC, Inc., a veterinary cancer therapeutics company, announced that TANOVEA®-CA1 is now commercially available in the U.S. for purchase by licensed veterinarians. TANOVEA-CA1 was recently granted conditional approval by the … Keep Reading

Why Pet Health Is The Focus Of A New Biotech Sector

Source: Life Science Leader By Cathy Yarbrough, Contributing Editor Follow Me On Twitter @sciencematter For Aratana Therapeutics, 2016 was a banner year. The biotech company, founded in 2010, achieved FDA approvals for three of its 10 pipeline drugs. Last year the Kansas … Keep Reading